Startup Alumis raises $259 million as it prepares for psoriasis trial
San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
Read Original Article: Startup Alumis raises $259 million as it prepares for psoriasis trial »
